MIRM
Mirum Pharmaceuticals
October 12, 2026 · pre-market
- Rarity
- 1.98
- Peak move
- +10.68%
- Float cap
- $3.7B
Mirum Pharmaceuticals is a commercial-stage rare disease drugmaker focused on rare liver and rare genetic conditions. It sells LIVMARLI for Alagille syndrome and PFIC, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis to specialty hepatologists, geneticists and treatment centers in the United States, Europe and other markets. Its pipeline includes volixibat, brelovitug, zilurgisertib and MRM-3379.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
4 events · 0 from SEC or newswire · 0 timed with the moveclinical_readoutMirum Pharmaceuticals reported topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in patients 6 months and older with ultra-rare cholestatic liver diseases including biliary atresia, meeting the primary endpoint with a 0.98-point placebo-adjusted improvement in ItchRO(Obs) score (p=0.0004) and a 70.1% vs 3.5% reduction in serum bile acids, plus all five secondary endpoints; an sNDA is planned for H1 2027.
reg_fd_disclosureMirum Pharmaceuticals announced it would host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET to share topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in patients 6 months and older with ultra-rare cholestatic liver diseases including biliary atresia.
analyst_ratingRBC Capital raised its price target on Mirum Pharmaceuticals to $155 from $135 while keeping an Outperform rating, as part of a broader biotech note adjusting models and previewing Q3 results.
analyst_ratingH.C. Wainwright raised its price target on Mirum Pharmaceuticals to $195 from $140 while maintaining a Buy rating.